why choose us

First received: January 4, 2023

Clinical Trial: Replicor Compassionate Access Program

Condition: Viral Hepatitis B
Viral Hepatitis D
Cirrhosis, Liver
Decompensated Cirrhosis
Asc

Study Type: Expanded Access


Official Title: Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infection

Brief Summary: The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to response to other other antiviral agents either approved or under development and who are in danger of progressing to decompensated cirrhosis.This compassionate access program will provide access to a once weekly regimen of subcutaneously (SC) administered REP 2139-Mg for a period of 48 weeks…

Read more